Bank of New York Mellon’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Bank of New York Mellon’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-128,937	Closed	-$5.99M	–	4459
2023 Q2	$5.99M	Sell	128,937 -2,447	-2%	-$84.6K	﹤0.01%	2224
2023 Q1	$3.76M	Sell	131,384 -5,598	-4%	-$166K	﹤0.01%	2451
2022 Q4	$4.27M	Buy	136,982 +42,118	+44%	+$1.37M	﹤0.01%	2428
2022 Q3	$1.92M	Buy	94,864 +23,453	+33%	+$427K	﹤0.01%	2881
2022 Q2	$1.11M	Buy	71,411 +32,876	+85%	+$565K	﹤0.01%	3166
2022 Q1	$737K	Buy	38,535 +5,192	+16%	+$92.7K	﹤0.01%	3491
2021 Q4	$844K	Buy	+33,343	New	+$977K	﹤0.01%	3480

Bank of New York Mellon's DICE Position: Q3 2023 in Review

Bank of New York Mellon sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 128,937 shares — an estimated $5.99M sold.

Bank of New York Mellon first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $5.99M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

Bank of New York Mellon reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Bank of New York Mellon sold 128,937 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $5.99M.
Bank of New York Mellon first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Bank of New York Mellon's DICE Therapeutics, Inc. Common Stock position peaked at $5.99M in Q2 2023.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Bank of New York Mellon's 13F filing for Q3 2023, filed 24 Oct 2023.